AZADINE 150 MG

Among the medicines listed for MDS; AML, Azacitidine has a defined role in Myelodysplastic syndromes; acute myeloid leukemia in patients for whom intensive induction is unsuitable; other hematologic settings. Incorporates into nucleic acids and inhibits DNA methyltransferase, promoting hypomethylation and altered gene expression. Its pharmacological class is DNA methyltransferase inhibitor. Its epigenetic action alters DNA methylation patterns and gene expression, an approach particularly relevant to myeloid malignancies. The database categorizes it as Epigenetic Therapy; Hypomethylating Agent and records regimen examples such as Azacitidine monotherapy; azacitidine + venetoclax; azacitidine-based AML/MDS regimens. These combinations indicate how the agent fits into broader treatment programs rather than functioning as a universal therapy for every cancer in the tumor group. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Clinical interpretation should include the disease stage, histology, treatment history, and any molecular or receptor feature expressly named in the indication. The mechanism is useful for understanding why those selection criteria matter and why another drug from the same broad category may not be interchangeable. This summary has been written for an oncology medicines reference database and does not attempt to prescribe therapy for an individual patient. Because labels and guideline-supported uses can change, current product information should be checked when the entry is applied clinically.